Sixty-one patients with pre-treated metastatic CCA carrying FGFR2 alterations were enrolled in a phase 2 (NCT02150967), single arm clinical trial investigating the efficacy of BGJ398, a potent and selective ATP-competitive inhibitor for FGFR1/2/3. This evidence concerns the gene FGFR2 and cholangiocarcinoma.